Our company was formed for the purpose of commercializing innovative therapies qualifying for FDA approval under the section 505 b(2) regulatory approval pathway for new formulations of previously approved drugs. The company’s initial product candidate is a proprietary oral suspension spray formulation of sildenafil citrate, the active ingredient in VIAGRA®. Our mission is to develop patient-focused solutions and must-have medicines by applying our innovative science and technologies to enhance currently marketed drugs with well-known pharmacology profiles.

Our leadership team is comprised of veterans in the biotech and specialty pharmaceutical space, with decades of experience in developing and marketing disruptive drug products. Our collective expertise covers all aspects of drug development and commercialization including: preparation of investigational new drug (IND) and new drug (NDA) applications; obtaining FDA and EMA approvals for numerous drug products; and launching prescription and OTC drugs in the United States. In addition, members of our leadership team are experienced in investor relations and public relations and are adept at managing healthcare capital markets and structuring and executing strategic transactions.